Study on the effect of itopride combined with rabeprazole on reflux esophagitis
Objective To explore the effect of itopride combined with rabeprazole on reflux esophagitis.Methods 130 patients with reflux esophagitis were divided into a non-itopride group and an itopride group according to the random numerical table,with 65 patients in each group.The patients in the non-itopride group were treated with rabeprazole,while the patients in the itopride group were treated with itopride on the basis of the non-itopride group.The time for symptom resolution,clinical efficacy,and esophageal motility indicators and adverse reactions were compared between the two groups.Results The total effective rate of itopride group was 96.92%(63/65),which was significantly higher than 75.38%(49/65)of non-itopride group(P<0.05).The resolution time of acid reflux and heartburn,abdominal distension,belching,epigastric pain and nausea and vomiting in itopride group were(7.93±1.26),(8.12±1.24),(7.24±1.38),(6.52±1.13)and(5.93±1.54)d,which were significantly shorter than(10.58±1.35),(11.25±2.37),(12.52±3.05),(9.54±1.52)and(9.46±1.75)d in non-itopride group(P<0.05).After treatment,the percentage of reflux time in upright position was(1.86±0.45)%,the percentage of reflux time in supine position was(2.71±0.95)%and the percentage of total reflux time was(4.65±1.37)%in itopride group,which were significantly lower than(4.52±1.63)%,(5.47±1.38)%and(10.56±3.28)%in non-itopride group;the esophageal sphincter pressure of(4.58±0.52)kPa in itopride group was significantly higher than(2.63±0.25)kPa in non-itopride group(P<0.05).The incidence of adverse reactions after medication in itopride group was 12.31%(8/65),which was not statistically significant from 9.23%(6/65)in non-itopride group(P>0.05).Conclusion On the basis of rabeprazole acid suppression therapy,combination with itopride can effectively promote the normalization of esophageal mucosal lesions,improve patients'esophageal motility indicators and clinical symptoms,shorten the patient's course,enhance clinical efficacy.It is safe and reliable.
ItoprideRabeprazoleCombination therapyReflux esophagitisMucosal redness and swellingDrug safety
万方数据
维普
